×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
Back to Agenda
Session 9 Track 2: Extra/Non-Hepatic Delivery
Session Chair(s)
Jeffrey Foy, PhD
Vice President, Toxicology
PepGen Inc., United States
Representative Invited
FDA, United States
This session will describe strategies for targeting extra-hepatic organs and will feature data from sponsor programs. Delivery technologies, nonclinical study design considerations, and pharmacology, ADME, and toxicology data will be discussed.
Learning Objective : At the conclusion of this session, participants should be able to:- Recognize current efforts to deliver oligonucleotide-based products to cells or organs outside of the liver
- Have a greater understanding of the challenges associated with delivering oligos to muscle, lung, and brain
Speaker(s)
Development of a Novel Muscle-targeted Antibody Oligonucleotide Conjugate for the Treatment of Myotonic Dystrophy Type 1: Toxicology and Regulatory Approaches and Considerations
Representative Invited
Avidity Biosciences, United States
Nonclinical Development of Inhaled Oligonucleotides: Nothing Good Comes Easily
Jessica Grieves, DVM, PhD
Ionis Pharmaceuticals, United States
Director, Pathology and Nonclinical Development
Brain Delivery of Oligonucleotide-based Therapeutics: Challenges and Accomplishments
Jinhee Yang, PhD
BIORCHESTRA Co., Ltd., Korea, Republic of
Director
Have an account?